中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-09-07
UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR OVERWEIGHT OR OBESITY IN CHINA
Learn More
2026-09-07
Significant Progress in Innovative Drug R&D and Continued Globalization Efforts Profit Attributable to Owners of the Company Reached Approximately RMB347.6 Million
Learn More
2026-08-12
FDA APPROVAL OF IND FOR THE GROUP’S PRODUCT UBT48128 TABLETS
Learn More
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
All News
Select Year
2026
2025
2024
TUL Ranks 23rd in the “2023 Top 100 Chinese Pharmaceutical Industry Enterprises”
2024-09-20
TUL Receives “ESG Excellence in Comprehensive Governance” Award
2024-09-13
Zhuhai United Laboratories Co., Ltd. Passes German GMP Inspection
2024-09-05
Revenue Continues to Grow! TUL Announces 2024 Interim Results
2024-09-05
TUL Participates in the 2024 Diabetes Education and Management Academic Conference
2024-08-19
TUL Participates in the 21st Endocrinology Academic Conference of the Chinese Medical Association
2024-08-13
Zhuhai United Laboratories Co., Ltd. Named a “Provincial Manufacturing Single Champion Enterprise” in Guangdong Province
2024-08-13
UBT251 Injection Completes Phase Ia Clinical Study in China
2024-08-13
Mayor of Christchurch, New Zealand Visits TUL for Exchange and Cooperation
2024-08-05
Prev
1
...
12
13
14
15
16
17
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
